legal status by jurisdiction
In the United States, ibogaine is a federal Schedule I controlled substance. There is no lawful clinical access domestically, for any indication.
Clinics operate in Mexico, where regulatory oversight varies significantly by facility. That variability is exactly why due diligence on any specific clinic matters more than the fact that ibogaine is legal to administer there.
Canada allows case-by-case access under a special access program for serious conditions; some therapies remain prescription-only once approved through that pathway.
To understand the US legal picture in more detail, see this practical overview of ibogaine in USA. Legal status can change and varies by state on adjacent questions (like possession); confirm current rules with counsel rather than relying on any single page, including this one.
anti-doping status: banned, with no exemption
Under the WADA Code, ibogaine falls within the S0 category of non-approved substances. S0 substances are prohibited at all times — in competition and out of competition alike.
There is no therapeutic use exemption for S0 substances. Because S0 covers substances that lack a formal approval pathway, there's no TUE mechanism to seek here, unlike some other prohibited categories. A positive test carries the same consequences whether the substance was taken during a training camp, an off-season recovery protocol, or immediately before competition.
US boxing programs typically coordinate with USADA or an analogous national anti-doping agency. Get written guidance from that body before any decision is made, and document the timeline — verbal assurances from a clinic about "clearing your system" are not a defense in an anti-doping proceeding.
Under S0 of the WADA Code, non-approved substances are prohibited at all times. Athletes should confirm directly with their WADA- or USADA-aligned liaison that ibogaine is not permitted in or out of competition before making any plan.
what this means practically
A positive test or an admission of use can trigger a suspension independent of whether the substance produced any performance effect — S0 status makes intent or benefit irrelevant to the violation.
Detection windows for ibogaine and noribogaine can extend well beyond the acute experience given noribogaine's longer half-life; "it'll be out of my system by fight week" is not a reliable assumption.
If addiction treatment is the actual goal, discuss with your medical and legal team whether an evidence-based, non-prohibited alternative achieves the same outcome without the anti-doping exposure — see the addiction & pain management page for that comparison.